All In Biotech

NDA 021348 · Actelion

Zavesca

Miglustat · Oral · Glucosylceramide Synthase Inhibitor; Enzyme Stabilizer

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Dec 8, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jul 31, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

10 Phase 3, 2 recruiting

FAERS reports

1,085

967 serious, 311 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 25, 2023.

Miglustat is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ). 1.1 Type 1 Gaucher Disease Miglustat is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).

Mechanism: Type 1 Gaucher disease is caused by a functional deficiency of glucocerebrosidase, the enzyme that mediates the degradation of the glycosphingolipid glucosylceramide. Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. Miglustat helps reduce the rate of glycosphingolipid biosynthesis so that the amount of glycosphingolipid substrate is reduced to a level which allows the residual activity of the deficient glucocerebrosidase enzyme to be more...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 2003 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
1 products under this application
  • ZAVESCA · MIGLUSTAT 100MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Miglustat" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea163
  • death153
  • seizure112
  • niemann-pick disease97
  • weight decreased97
  • pneumonia86
  • disease progression85
  • tremor75
  • condition aggravated74
  • off label use73
  • dysphagia66
  • pyrexia61

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200513
200611
20079
200811
20096
201056
201156
201286
201370
201455
201589
201674
201781
201883
201952
202052
2021115
202228
202333
202427
202540
202628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zavesca (Miglustat)

2024 spending

$1.3M

Beneficiaries

n/a

56 claims

Per beneficiary

n/a

$188.17 per unit

View as table
YearSpending
2020$1,367,726
2021$1,819,181
2022$2,046,912
2023$2,123,383
2024$1,343,537

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.